When they crack the solid tumour market? They haven't cracked...

When they crack the solid tumour market? They haven't cracked the liquid tumour market have they? Words like glorious, beautiful, immensely seem to flow like maple syrup off LC's tongue, but for some reason she's unable to describe clearly exactly what science they are doing. For example she says in that interview posted below that CF33 'expresses' CD19 (it doesn't and it can't - it's a virus - a virus needs a host cell for gene expression), that CD19 only appears in blood cancers' (CD19 is a general marker for B cells) and that this new deal gives 'them patient data for 84 blood cancer types' (it actually gives them data on 84 patients.) Even on the imugene website they are confused, in one paragraph saying 'In this study, the COH team used CF33 OV to selectively deliver CD19' and in the next 'CD19-encoding OV'. So what is the actual clear story? I mean I think I could produce one out of the garbled bits and pieces we get, but I can't be sure that they clearly understand it that way.

Happy to be corrected in any way.